Chapter 49
Institution: Regional High-Security Psychiatric Unit, Mazowieckie, Poland
Document Type: Comprehensive Psychiatric Evaluation emotional expression markedly reduced
Thought Form
Coherent but abstract, with symbolic substitutions
Thought Content
Persistent paranoid ideation (being watched, evaluated, anticipated)
Passive death ideation remains present post-attempt
Perception
No overt hallucinations reported, though patient describes “presence-like awareness”
Insight
Limited
Judgment
Impaired
Diagnostic Formulation (DSM-5 / ICD-10 aligned)
Schizophrenia, Paranoid Type (Primary, chronic, severe)
Major Depressive Disorder, Severe, recurrent
Generalized Anxiety Disorder (chronic)
Insomnia Disorder (severe, persistent)
Complex Post-Traumatic Stress Disorder (CPTSD) – strongly indicated
Clinical Course
Across repeated sessions, the patient presents with:
Persistent internalized distress masked by controlled exterior
High cognitive function with detached emotional processing
Ongoing hypervigilance and environmental scanning
Difficulty distinguishing internal vs. external threat attribution
Periods of near-complete emotional flattening followed by intense internal agitation (self-reported)
Patient demonstrates a pattern of containment rather than resolution. Symptoms are not absent, but suppressed beneath structured behavior.
Pharmacological Management (High-Intensity Regimen)
Given the severity, chronicity, and suicide risk, patient has been initiated on an aggressive multi-axis pharmacological protocol:
Primary Antipsychotic:
Olanzapine – 20 mg/day (maximum recommended dose)
Administered 10 mg morning / 10 mg evening
Target: paranoid ideation, cognitive distortion, agitation
Secondary Antipsychotic (Augmentation):
Quetiapine – 800 mg/day (maximum recommended dose)
Administered in divided doses
Target: mood stabilization, sedation, intrusive thought dampening
Adjunct Mood Stabilization / Sedation Layer:
Valproate (Sodium Valproate) – 2000 mg/day
Serum levels monitored
Target: affective instability, impulse control
Anxiolytic (Daytime Control):
Clonazepam – 4 mg/day (upper therapeutic range)
Administered 1 mg x 4
Target: persistent anxiety, somatic tension, hypervigilance
Night Sedation Protocol (Combined):
Mirtazapine – 45 mg nightly (maximum dose)
Zolpidem – 10 mg nightly (maximum standard dose)
Promethazine – 50 mg nightly
Despite combination therapy, patient reports only partial sleep induction, indicating severity of underlying insomnia.
Clinical Interpretation of Medication Load
The patient is currently under heavy pharmacological sedation and stabilization protocol, indicative of:
Severe psychiatric burden
High relapse and self-harm risk
Need for layered symptom suppression rather than single-agent control
Despite this, full symptom remission is not achieved, suggesting deeply ingrained pathology.
Response to Treatment
Following medication initiation:
External agitation reduced
Behavioral compliance increased
Sleep marginally improved (still clinically insufficient)
Paranoid ideation persists but is less behaviorally dominant
Most notable development:
Patient has initiated compulsive writing behavior, producing structured and reflective text.
This appears to function as:
Cognitive organization
Emotional externalization
Controlled self-expression
This behavior is assessed as clinically beneficial and should be encouraged under supervision.
Risk Assessment
High chronic suicide risk
History of severe, near-lethal self-harm
Persistent passive death ideation
Emotional suppression increases unpredictability
Patient remains unsuitable for discharge.
Prognosis
Guarded.
Patient demonstrates capacity for:
Insight (partial, intellectualized)
Engagement (controlled, selective)
However:
Core pathology remains deeply embedded
Long-term pharmacological dependence likely
Conclusion
Rowan presents as a severely psychiatrically compromised individual, whose internal state remains unstable despite intensive intervention.
Recent behavioral shift toward structured writing suggests a potential adaptive outlet, though not indicative of recovery.
Patient is stabilized but not well.
Signed,
Dr. Kazimierz Lewandowski, MD